The drugmaker has become a clear winner with its weight-loss drugs. Now, with a pill under development, the company should ...

LLY has slid 15.7% over the past year, but surging demand for Mounjaro and Zepbound could revive the stock's momentum.

Eli Lilly and Company LLY announced earlier this week that its popular obesity drug, Zepbound (tirzepatide) outperformed rival Novo Nordisk’s NVO Wegovy (semaglutide) in a weight-loss head-to ...

Eli Lilly’s Zepbound transformed weight loss drug market since debut 18 months ago 4.5 million people reportedly taking Lilly ...

The only approved medicine that does that is Zepbound, the weight loss therapy marketed by Eli Lilly. Zepbound has been a major hit, with incredibly fast-growing sales.

This change is happening because there’s another covered medication that’s safe and effective for your condition and may cost ...

The only approved medicine that does that is Zepbound, the weight loss therapy marketed by Eli Lilly. Zepbound has been a major hit, with incredibly fast-growing sales.

Lilly’s stock has gone up by 590% in the past five years, mainly due to its successful new drug launches, particularly Mounjaro and Zepbound, and its solid pipeline potential.

The only approved medicine that does that is Zepbound, the weight loss therapy marketed by Eli Lilly. Zepbound has been a major hit, with incredibly fast-growing sales.

The latest Zepbound data bodes well for Lilly and could help establish the drug as the new standard for obesity medications.